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Dregistry will help to clarify the surgical applications and
long-term results of this procedure.
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DrGeorg Lutter (Kiel, Germany). Congratulations on your lat-
est result. I want to ask you whether you measured the length of
your neochords between your apex and your posterior leaflet.
Did you put it more toward the posterolateral side, meaning that
this is more stable than seen in the patients in whom you put
your neochords directly towards the apex, and therefore did you
measure the length over time between the apex and the posterior
leaflet? We would like to know how to get stable results referring
to your neochords. What did you observe in your successful cases
with your repair of your posterior leaflet?
Dr Speziali. Proper tensioning of the neochords is a critical
element of this procedure, and intraoperatively we fill the heart
and we tension the neochords under direct visualization. We
pull the neochords enough to make the prolapse go away. ThereThe Journal of Thoracic and Cis a difference between the apex and the posterolateral segment
of the LV regarding the distance with the mitral annular plane:
the apex distance to the mitral plane is fixed, but the posterolat-
eral segment moves in and out during diastole and systole, and I
think that also reduces the snap on the neochords when the valve
closes. So it is not just a matter of length, it is a matter of force
applied to the chord that gets transmitted to the chord-leaflet
interface.
It is difficult to figure out in a few patients exactly what the
major determinant of neochordal tension and durability is, also
from an engineering and geometric standpoint.
Dr Lutter. Could you also imagine going with your NeoChord
device into one of the papillary muscles and then afterward going
into your posterior leaflet, P2, and fixing it over there?
Dr Speziali. I don’t want to stick that instrument through the
papillary muscle, because it is a lot of muscle you’d have to go
through. Possibly when we come out of the apex, however, we
can go back with a French eye needle and then reach the head of
the papillary muscle and then out again. It has been done in a
few of these cases.
Dr Thierry Mesana (Ottawa, Ontario, Canada). Congratula-
tions. This is a very nice device. I have 2 technical questions.
Maybe one you can answer; the other one you have to wait a
few years to answer.
First, can you really address P1 or P3 and not only P2? Most of
these posterior leaflet prolapses, or maybe half of them, are not
simple P2 prolapse. Second, do you think that by having your
device positioned in the apex and having to go through a thoraco-
tomy, you can induce adhesions and transformation of the apex and
then gradually with time have some fibrotic formation here? They
are going to change the anatomy of the chord itself implanted in
the apex. But it’s a nice study.
Dr Speziali. For the second question, we put a purse-string
suture with pledgets as for a transcatheter aortic valve implan-
tation, and that has not been a problem so far. The sutures
are actually anchored to the pledgets, not to the muscle itself.
So I think it’s unlikely that the pledget migrates or that changes
the geometry.
What was the first question?
Dr Williams. Whether you can treat P1 or P3, anterior leaflet.
Dr Speziali. The inclusion criteria didn’t specify P2.
Dr Williams. Do you think you can with this device? Do you
think you can treat P1 and P3?
Dr Speziali. Yes, I meant that we have done this. Both P1 and
P3 were treated in this series.ardiovascular Surgery c Volume 147, Number 1 99
